Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Isopropyl Unoprostone
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Recipient : Mallinckrodt Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 23, 2011
Lead Product(s) : Isopropyl Unoprostone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Recipient : Mallinckrodt Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Recipient : Mallinckrodt Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2011
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Recipient : Mallinckrodt Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable